This page shows the latest faldaprevir news and features for those working in and with pharma, biotech and healthcare.
Boehringer's faldaprevir set for rapid review in Europe. More competition in emerging hepatitis C market. ... Boehringer Ingelheim's new hepatitis C virus ( HCV) therapy faldaprevir could be on the market in the EU as early as the second half of 2014,
Boehringer says faldaprevir does well in Asian hepatitis C patients. Trial success in patients from Korea, Japan and Taiwan. ... Boehringer Ingelheim's second-generation hepatitis C virus protease inhibitor faldaprevir achieved a viral cure rate of
The combination of two of Boehringer's oral hepatitis C drugs - faldaprevir and BI 207127 - plus ribavirin achieved viral cure rate of up to 85 per cent after just 28 weeks' treatment ... Faldaprevir is a once-daily protease inhibitor while BI 207127 is
Other drugs emerging in the protease inhibitor class include Boehringer Ingelheim's faldaprevir, Merck's vaniprevir, Bristol-Myers Squibb's asunaprevir and AbbVie's ABT 450, which also claim superior viral cure rates and milder side
The launch of the US-focused HepCRedefined.com site came on the day the pharma company moved its interferon-free hep C regimen, which combines faldaprevir and BI 207127, into phase III trials.
More from news
Approximately 3 fully matching, plus 2 partially matching documents found.